StageZero Life Sciences Ltd T.SZLS

Alternate Symbol(s): SZLSF

Healthcare Biotechnology

StageZero Life Sciences, Ltd. is a Canada-based vertically integrated healthcare company. The Company is engaged in improving the early detection and management of cancer and other chronic diseases through diagnostics and telehealth programs that provide clinical interventions to assist patients who have cancer (COC Protocol), and help patients reduce the risk of developing late-stage disease (AVRT). Its test, Aristotle, is the first mRNA multi-cancer panel for simultaneously screening for multiple cancers from a single sample of blood with high sensitivity and specificity for each cancer. Aristotle uses mRNA technology to identify the molecular signatures of multiple cancer types and is built on the Company's patented technology platform, the Sentinel Principle. The Care Oncology Clinic offers a supervised treatment regimen (the COC Protocol) for people diagnosed with cancer of any type or stage. Its ColonSentry is a proprietary blood test for screening for Colorectal Cancer.

TSX:SZLS - Post by User

StageZero Life Sciences Ltd

Bullboard Posts

Post by scorpio40on May 15, 2017 5:34pm

153 Views

Post# 26246889

Conference call May 18th, 2017

GeneNews to hold IDL operations conference call May 18

GeneNews Ltd (2) (C:GEN)
Shares Issued 87,929,627
Last Close 5/15/2017 $0.245
Monday May 15 2017 - News Release

Mr. James Howard-Tripp reports

GENENEWS TO HOST IDL BUSINESS UPDATE CONFERENCE CALL ON MAY 18, 2017

In response to investor and media inquiries received about the operations and partnership activities at its Virginia-based Innovative Diagnostic Laboratory (IDL) clinical reference lab, GeneNews Ltd.'s chairman and chief executive officer, James Howard-Tripp, will host a conference call at 4:30 p.m. ET on May 18, 2017, to discuss IDL's business.

IDL Business Update Conference Call Details:

 Date:        Thursday, May 18, 2017

 Time:        4:30 p.m. ET

 Live Call:  (888) 231-8191 (Canada and the United States)

                  (647) 427-7450 (International)

                  Conference ID: 24600536

 Replay:     (855) 859-2056 (Canada and the United States)

                  (416) 849-0833 (International)

                  Password: 24600536

The call will also be broadcast live and archived on the Company's website at www.GeneNews.com in the Investor's section.

About GeneNews

GeneNews, an innovator in the liquid biopsy space, is committed to becoming a leader in advanced diagnostics and personalized medicine, serving as a strong commercialization outlet for early detection of cancer and other chronic diseases. Our mission is to identify, assess and make commercially available a comprehensive menu of diagnostics that provide physicians and patients with personalized clinical intelligence and actionable information to improve health out-comes through the early diagnosis of disease. Our Richmond, Virginia-based Innovative Diagnostic Laboratory clinical reference lab specializes in traditional and advanced clinical evidence-based blood testing that helps find, understand, and address cancer risk in patient populations. Currently, IDL offers risk assessment blood tests for four prevalent cancer types - colon, lung, prostate and breast. GeneNews' common shares trade on the Toronto Stock Exchange under the symbol 'GEN'. More information on GeneNews and IDL can be found at www.GeneNews.com and www.myinnovativelab.com, respectively.

We seek Safe Harbor.

Bullboard Posts

Three micro-cap value stocks trading at peak pessimism